Adverum Biotechnologies, Inc.

NasdaqCM:ADVM Voorraadrapport

Marktkapitalisatie: US$154.1m

Adverum Biotechnologies Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Adverum Biotechnologies's earnings have been declining at an average annual rate of -10.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 7.4% per year.

Belangrijke informatie

-10.5%

Groei van de winst

-0.8%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei7.4%
Rendement op eigen vermogen-59.4%
Nettomargen/a
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Feb 24
We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Sep 07
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Aug 11

Adverum gains 13% to reach three-month high after Truist upgrade

Jul 07

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

May 12
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Jul 17
We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Adverum Biotechnologies: An Uncertain Path Forward

May 05

Adverum Bio presents long-term data from ADVM-022 trial in wet AMD

May 03

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Apr 06
We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

Feb 13
Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy

Feb 02

Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares

Jan 22
Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares

Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market

Jan 11

Adverum Biotechnologies announces new GMP gene therapy manufacturing facility

Jan 07

How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?

Dec 31
How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?

Opbrengsten en kosten

Hoe Adverum Biotechnologies geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:ADVM Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 240-100400
31 Mar 240-113480
31 Dec 234-117500
30 Sep 234-126480
30 Jun 234-133510
31 Mar 234-146520
31 Dec 220-155550
30 Sep 220-156570
30 Jun 220-154540
31 Mar 220-155620
31 Dec 218-146630
30 Sep 218-149660
30 Jun 218-138630
31 Mar 218-123520
31 Dec 200-118450
30 Sep 200-99390
30 Jun 200-87350
31 Mar 200-73320
31 Dec 190-64280
30 Sep 190-61250
30 Jun 191-66230
31 Mar 191-70250
31 Dec 182-73250
30 Sep 182-72220
30 Jun 182-65230
31 Mar 182-57180
31 Dec 172-56200
30 Sep 172-64220
30 Jun 172-64220
31 Mar 172-114200
31 Dec 161-114200
30 Sep 162-105190
30 Jun 162-105200
31 Mar 162-53230
31 Dec 152-47200
30 Sep 152-44200
30 Jun 151-38150
31 Mar 151-36110
31 Dec 141-2980
30 Sep 140-2250
30 Jun 140-1430
31 Mar 140-720
31 Dec 130-510

Kwaliteitswinsten: ADVM is currently unprofitable.

Groeiende winstmarge: ADVM is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: ADVM is unprofitable, and losses have increased over the past 5 years at a rate of 10.5% per year.

Versnelling van de groei: Unable to compare ADVM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: ADVM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement op eigen vermogen

Hoge ROE: ADVM has a negative Return on Equity (-59.43%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden